Parmesar Kevon, Raj Kavita
Department of Haematology, Kings College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK; Kings College London, Kings College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK.
Department of Haematology, Kings College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK; Department of Haematology, Guys and St. Thomas' NHS Foundation Trust, Great Maze Pond, London SE1 9RT, UK.
Adv Hematol. 2016;2016:3905907. doi: 10.1155/2016/3905907. Epub 2016 May 30.
Haematopoietic stem cell transplantation is a well-established treatment option for both hematological malignancies and nonmalignant conditions such as aplastic anemia and haemoglobinopathies. For those patients lacking a suitable matched sibling or matched unrelated donor, haploidentical donors are an alternative expedient donor pool. Historically, haploidentical transplantation led to high rates of graft rejection and GVHD. Strategies to circumvent these issues include T cell depletion and management of complications thereof or T replete transplants with GVHD prophylaxis. This review is an overview of these strategies and contemporaneous outcomes for hematological malignancies in adult haploidentical stem cell transplant recipients.
造血干细胞移植是治疗血液系统恶性肿瘤以及再生障碍性贫血和血红蛋白病等非恶性疾病的一种成熟治疗选择。对于那些缺乏合适的同胞全相合或非血缘全相合供者的患者，单倍体相合供者是另一个权宜的供者来源。从历史上看，单倍体相合移植导致较高的移植物排斥率和移植物抗宿主病（GVHD）发生率。规避这些问题的策略包括T细胞去除及其并发症的处理，或采用预防GVHD的T细胞未去除的移植。本文综述了这些策略以及成年单倍体相合干细胞移植受者血液系统恶性肿瘤的同期治疗结果。
